MedicineNews.net

Development of MDCO-216, an investigational cholesterol efflux promoter, discontinued due to poor efficacy

Immediate discontinuation of the clinical development program for MDCO-216, an investigational cholesterol efflux promoter, was announced. Data from the MILANO-PILOT trial did not show drug effects ... read article

Glyxambi, a fixed-dose combination of Empagliflozin and Linagliptin, for the treatment of type 2 diabetes mellitus

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Glyxambi, intended for the ... read article

Qtern, a fixed-dose of Saxagliptin and Dapagliflozin, for adults with type 2 diabetes mellitus: positive opinion from CHMP

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion, recommending the approval of Qtern ( Saxagliptin and Dapagliflozin ) ... read article

Ixekizumab clears psoriasis in clinical trials

About 80% of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with Ixekizumab ( Taltz ), according to three large, long-term clinical trials led by ... read article

Efficacy of cinnamon in patients with type II diabetes mellitus

Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus type II, with conflicting results. Differences in baseline body mass index ( BMI ) of patient ... read article

Symptoms of insomnia in psoriasis are directly mediated by pruritus and pain

Psoriasis is an immune-mediated chronic inflammatory disorder which manifests as dermatologic lesions, and psoriatic arthritis in about 30% of cases. Psoriasis is associated with multiple comorbid ... read article

Epanova for the treatment of adults with severe hypertriglyceridaemia, approved by FDA

The Food and Drug Administration ( FDA ) has approved Epanova ( Omega-3-carboxylic acids ) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia ( triglycerid ... read article

Diabetes: Metformin associated with risk of low levels of thyroid hormone

Metformin, a commonly used drug for treating type 2 diabetes, is linked to an increased risk of low thyroid-stimulating hormone ( TSH ) levels in patients with hypothyroidism. Low levels of TSH can c ... read article

Myalept to treat congenital generalized or acquired generalized lipodystrophy

The FDA ( Food and Drug Administration ) has approved Myalept ( Metreleptin for injection ) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients wit ... read article

Saxagliptin, an antidiabetic drug : FDA to review heart failure risk

FDA’s request resulted from a study published in the New England Journal of Medicine ( NEJM ), which reported an increased rate of hospitalization for heart failure, when the heart does not pump ... read article

Myalept as replacement therapy to treat the complications of leptin deficiency

The Food and Drug Administration ( FDA ) has approved Myalept ( Metreleptin for injection ) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients wit ... read article

SGLT2 inhibitors: FDA has approved Invokana to treat type 2 diabetes

The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes is ... read article

Incretin mimetic drugs for type 2 diabetes: possible increased risk of pancreatitis and pre-cancerous findings of the pancreas

The FDA ( Food and Drug Administration ) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes cal ... read article

Cardiometabolic adverse reactions suspected of being associated with second-generation antipsychotics in children and adolescents

Excess weight and obesity in the general population are increasing problems throughout the Western world, and this rise has also been observed in children and adolescents.Weight gain and obesity are k ... read article

Forxiga, a SGLT2 inhibitor, approved in Europe for treatment of type 2 diabetes

Forxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose cotransporter 2 ) class drug. Forxiga has obtained marketing approval by the European Commission ( EC ) for the treatment of type 2 diabet ... read article